Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

BACKGROUND: The combination of bevacizumab and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could prolong progression-free survival (PFS) in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC). Our study investigated the clinical and molecular factors tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yongchang, Zeng, Liang, Zhang, Xiangyu, Li, Yizhi, Liu, Lingli, Xu, Qinqin, Yang, Haiyan, Jiang, Wenjuan, Lizaso, Analyn, Qiu, Luting, Hou, Ting, Liu, Jun, Peng, Ling, Yang, Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525046/
https://www.ncbi.nlm.nih.gov/pubmed/34663309
http://dx.doi.org/10.1186/s12916-021-02118-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525046/
https://www.ncbi.nlm.nih.gov/pubmed/34663309
http://dx.doi.org/10.1186/s12916-021-02118-x

Ejemplares similares